Rigel Pharma (RIGL) Tops Q3 EPS by 146c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.86 -0.04%
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
UTMD, GCBC, ORPB, More
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of $1.46. Revenue for the quarter came in at $69.46 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primis Financial (FRST) Misses Q3 EPS by 7c
- Galderma Group AG (GALD:SW) PT Raised to CHF220 at Goldman Sachs
- Axis Capital Limited Upgrades Balkrishna Industries Ltd. (BIL:IN) to Add (2)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
